Pharmstandard more than doubles sales revenue in Q1
MOSCOW. April 28 (Interfax) - OJSC Pharmstandard more than doubled its sales revenue in the first quarter of 2011 to 11.67 billion rubles in comparison with the same period of 2010, the company said in a statement posted on its webpage.
The statement said: "According to a non-audited report, Pharmstandard's sales in 1Q2011 grew by 103.8% and totaled RUR 11,670.2 million which represents an increase of RUR 5,943.1 million in relation to RUR 5,727.1 million in 1Q2010."
"The shares of pharmaceutical products and medical equipment in the Company's overall sales equaled 99.1% and 0.93% respectively."
"In 1Q 2011, sales of pharmaceutical products grew by 105.2% and reached RUR 11,563.6 million in comparison to RUR 5,635.8 million in 1Q 2010. The total increase amounted to RUR5,927.8 million.
"In the total sales structure, 46.3% represented sales of the pharmaceuticals produced by the Company, and 51.4% represented TPP sales.
"In 1Q 2011 the sales results include proceeds from the new subsidiary PJSC Biolek (Ukraine). Pharmstandard holds 55% of ordinary voting shares of Biolek. Sales of PJSC Biolek amounted to RUR 85.1 million or 0.7% of the overall volume of pharmaceutical products.
"Sales of Company's own pharmaceutical products, including the results of PJSC Biolek, increased by 21.8% or RUR 996.4 million and totaled RUR 5,560.4 million.
"The shares of the OTC and Rx preparations in the structure of sales of Pharmstandard's own products amounted to 79.3% and 16.0%, respectively.
"Sales of Pharmstandard's own OTC products increased by 20.4% or RUR 762.5 million and totaled RUR 4,494.1 million. Arbidol ,Pentalgin, Complivit, Afobazol, Flucostat were the top-selling brands
"Sales of prescription drugs (Rx) manufactured by Pharmstandard grew by 11.1% (RUR 91.0 million) and totaled RUR 908.2 million. Phosphogliv, Rastan, Combilipen, Biosulin and Azitrox were the top-selling brands.
"TPP sales grew by 460.1% or RUR 4,931.3 and reached RUR 6,003.2 million.
"The company's revenue from the sales of medical equipment in 1Q2011 grew by RUR 15.3 million or 16.7% and amounted to RUR 106.6 million vs RUR 93.1 million in 1Q 2010."